INTRODUCTION {#s1}
============

Pathogenic rare variants in *OPA3* have previously been shown to cause optic atrophy, with either autosomal dominant or autosomal recessive inheritance ([@BOURNEMCS001156C14]). The OPA3 protein primarily localizes at the inner mitochondrial membrane and possibly the outer mitochondrial membrane ([@BOURNEMCS001156C7]). Although the exact function of OPA3 is unknown, previous studies have suggested OPA3 involvement in regulating mitochondrial morphology ([@BOURNEMCS001156C13]; [@BOURNEMCS001156C7]).

Costeff syndrome, also known as type III 3-methylglutaconic aciduria, is caused by autosomal recessive *OPA3* mutations and, to date, has been reported almost exclusively among patients of Iraqi-Jewish descent ([@BOURNEMCS001156C17]). Patients with Costeff syndrome usually present with early-onset bilateral optic atrophy, later-onset spasticity, extrapyramidal dysfunction, cerebellar ataxia, and mild cognitive defect ([@BOURNEMCS001156C1]; [@BOURNEMCS001156C16]). A significantly increased level of 3-methylglutaconic acid (\>40 µmol/mmol Cr) in the urine of an individual with optic atrophy confirms a diagnosis of Costeff syndrome ([@BOURNEMCS001156C10]; [@BOURNEMCS001156C9]; [@BOURNEMCS001156C19]).

Autosomal dominant *OPA3* mutations causing optic atrophy appear to be less common than the recessive form, and the phenotypes, attributable to these rare variants, are more variable ([@BOURNEMCS001156C14]). Autosomal dominant optic atrophy (ADOA) caused by an *OPA3* mutation usually presents with optic atrophy and cataracts, although some patients have been seen with isolated optic atrophy ([@BOURNEMCS001156C14]). Hearing loss, nystagmus, and glaucoma have also been observed in patients with ADOA caused by *OPA3* mutations ([@BOURNEMCS001156C14]). Peripheral neuropathy and ataxia in these cases were first described in 1961 by Garcin and coworkers among a French family that manifested autosomal dominant inheritance of optic atrophy and cataract. Follow-up studies by [@BOURNEMCS001156C10] attributed this family\'s disorder to a c.277G \> A, p.(Gly93Ser) mutation transition in exon 2 of *OPA3*, which cosegregated with the phenotype.

Here we describe a patient with optic atrophy, cataracts, ataxia, and peripheral and autonomic neuropathy associated with an autosomal dominant c.235C \> G p.(Leu79Val) mutation in exon 2 of the *OPA3* gene (National Center for Biotechnology Information \[NCBI\] reference sequence NM_025136.3).

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

The female Caucasian proband presented with nystagmus at birth and bilateral cataracts that were first detected at 3 mo of age. Her lenses were removed during her first year, but there was no apparent improvement in her best-corrected visual acuity. At age 6 yr, she was found to have optic nerve atrophy after a visual evoked potentials (VEP) test. The VEP test concluded that the patient had highly abnormal visual evoked potentials in both eyes. She was otherwise healthy until 12 yr of age when she started experiencing ataxia, which caused her to stumble. The ataxia initially manifested only in her lower limbs, and then her upper limbs began to show signs of ataxia at ∼15 yr of age. She started experiencing falls at age 17 and was formally diagnosed with peripheral neuropathy after nerve conduction studies were performed at age 21. The nerve conduction studies showed a complete absence of all sensory responses in the upper and lower extremities. Motor nerve conduction studies in the upper limbs were normal, and there were no findings that suggested demyelination.

The patient recalled a relatively rapid progression of her neuropathy between 17 and 27 yr of age, though the progression has slowed for the last few years. Her visual acuity has worsened since birth, decreasing from 20/200 as a young child to 20/450 currently. She also has symptoms of palinopsia with smearing effect, double vision, and visual snow. By age 23 yr, she had cutis marmorata in her extremities, a novel phenotype for *OPA3* mutations, suggesting some degree of vasomotor instability. She also has cerebellar findings including a marked intention tremor, dysdiadochokinesia, and mild dysarthria, suggesting there is a cerebellar component to her ataxia. She has an extrapyramidal component with some chorea, postural tremor, and vocal tremor. She has normal facial features with the exception of upslanting palpebral fissures and is of normal intelligence. The possibility of a secondary lipodystrophy was considered because she also has generalized wasting of muscle and subcutaneous fat, especially in the hands and forearms. She has diminished light touch sensation from knees distally and distal to the metacarpophalangeal joints of the hands. Blood biomarkers have been unremarkable over the last 10 yr, except for occasional mild neutropenia and mild elevations of creatine kinase and total cholesterol ([Table 1](#BOURNEMCS001156TB1){ref-type="table"}). Urinalysis has shown moderate ketones and a slightly elevated vitamin E, though urine organic acids found no evidence of 3-methylglutaconic aciduria as her 3-methylglutaconic acid level was 9 mmol/mol of creatinine (reference range \<20 mmol/mol Cr). Her electromyography (EMG) showed chronic neurogenic changes, and brain magnetic resonance imagings (MRIs) performed at ages 20 and 23 yr were normal with the exceptions of signs of bilateral optic nerve and chiasmal atrophy. There is no apparent cardiac involvement as demonstrated by a normal electrocardiogram and echocardiogram.

###### 

Serum biomarker concentrations

  Biomarker                    Patient serum concentration   Reference range
  ---------------------------- ----------------------------- -------------------
  Alanine aminotransferase     22 U/l                        \<36 U/l
  Albumin                      46 g/l                        35--50 g/l
  Alkaline phosphatase         55 U/l                        \<125 U/l
  Aspartate aminotransferase   29 U/l                        \<36 U/l
  Bilirubin                    14 µmol/l                     3--17 µmol/l
  Ceruloplasmin                235 mg/l                      220--455 mg/l
  Cholesterol                  5.0 mmol/l                    2.0--4.6 mmol/l
  HDL cholesterol              1.6 mmol/l                    \>1.1 mmol/l
  LDL cholesterol              3.1 mmol/l                    1.5--3.0 mmol/l
  Cholesterol-to-HDL ratio     3.1                           \>4.4
  Copper                       13.1 µmol/l                   11.3--25.2 µmol/l
  Creatine kinase              169 U/l                       \<140 U/l
  Ferritin                     15 µg/l                       15--200 µg/l
  Folate                       755 nmol/l                    \>12 nmol/l
  γ-Glutamyl transferase       14 U/l                        \<31 U/l
  Glucose (fasting)            4.7 mmol/l                    3.6--6.0 mmol/l
  Homocysteine                 7.0 mmol/l                    \<7.8 mmol/l
  Lactic acid                  0.7 mmol/l                    0.5--2.2 mmol/l
  Triglyceride                 0.6 mmol/l                    \<2.3 mmol/l
  Urea                         7 mmol/l                      2--9 mmol/l

HDL, high-density lipoprotein; LDL, low-density lipoprotein.

She experiences constant paresthesia and numbness in her extremities. Diminished light touch sensation in her hands and feet make it difficult for her to distinguish textures. She also experiences proximal muscle weakness. She has lost position sense in her distal interphalangeal joints in both her hands and feet. Deep tendon reflexes are absent in her ankles, knees, and wrists. She has hyperesthesia of her lower legs, particularly of the soles of her feet. She also has atrophy of the fat pads of her face and has experienced neuropathic pain in her hands and feet. She has an ataxic gait and has reduced hearing in her left ear (512 mHz). Her parents and two siblings showed no signs of sharing her phenotype.

Genomic Analysis {#s2b}
----------------

At age 20, medical genetics first assessed her to search for a potential diagnosis. She had normal chromosomes and a normal test for Friedreich\'s ataxia. Genes associated with Charcot--Marie--Tooth disease (*MPZ*, *MFN2*, and *GJB1*) were sequenced also, as Charcot--Marie--Tooth disease presents with progressive atrophy and muscle weakness secondary to neuropathy ([@BOURNEMCS001156C11]; [@BOURNEMCS001156C20]; [@BOURNEMCS001156C12]). The common duplication of *PMP22* was ruled out by clinical-grade testing, and genes known to cause lipodystrophy (*LMNA*, *PPARG*, *EMD*, *AGPAT2*, *BSCL2*) were also sequenced. No pathogenic variants were found in any of these genes. Testing of *OPA3* as a candidate gene by an external laboratory on a research basis did not identify any rare variants, so trio-based exome sequencing was performed on blood-derived DNA from the patient and her parents. The sequencing results identified a de novo missense variant (c.235C \> G p.\[Leu79Val\]) in the patient\'s *OPA3* gene (NCBI reference sequence NM_025136.3), a gene known to cause optic atrophy and cataracts ([@BOURNEMCS001156C10]; [@BOURNEMCS001156C2]). Sanger confirmation of the variant of interest was carried out using standard polymerase chain reaction (PCR) in the proband and in parental DNA. Sanger sequencing confirmed that the proband was heterozygous for the variant and that the variant was absent from both parents ([Fig. 1](#BOURNEMCS001156F1){ref-type="fig"}). The variant is absent from the Database for Short Genetic Variations (dbSNP) build 146, National Heart, Lung, and Blood Institute (NHLBI) Exome Variant Server, and Exome Aggregation Consortium (ExAC) ([Table 2](#BOURNEMCS001156TB2){ref-type="table"}). The genomic position is highly conserved in vertebrates and is predicted to be damaging by Combined Annotation-Dependent Depletion (CADD) (CADD version 1.3 score was 19.02), MutationTaster (probability 0.999311228255692), and Protein Variation Effect Analyzer (PROVEAN) software (PROVEAN score was −3.00, with anything less than −2.5 considered to be deleterious; [@BOURNEMCS001156C3]; [@BOURNEMCS001156C4]). *OPA3* has a residual variation intolerance score (RVIS) of 20.96, which suggests it is not a gene that is frequently seen to harbor rare benign mutations, thereby further supporting the pathogenicity of our de novo variant. Parental relatedness to the proband was confirmed. There were no other variants detected in any genes that are known to cause Charcot--Marie--Tooth disease or other diseases with a similar phenotype (average read coverage, 37.5×).

![Sanger sequencing traces with arrows indicating the mutation and a nearby single-nucleotide polymorphism (SNP). Traces show that the *OPA3* variant (Chr19:46,057,077C \> G p.(L79V) annotated per hg19) is de novo in the proband. The father is heterozygous for rs3826860, a synonymous variant that is annotated in the Database for Short Genetic Variations (dbSNP) at a nearby nucleotide (g.46,057,081A \> G; c.231T \> C; p.(Ala77=)); the proband and her mother are homozygous for the SNP, whereas only the proband is heterozygous for the mutation.](BourneMCS001156_F1){#BOURNEMCS001156F1}

###### 

*OPA3* variant summary

  Gene     Chr. (hg19)   Position             Mutation      Amino acid change   Inheritance   Public database reference^a^
  -------- ------------- -------------------- ------------- ------------------- ------------- ------------------------------
  *OPA3*   19            g.46,057,077G \> C   NM_025136.3   p.Leu79Val          De novo       Not described

^a^Public databases checked include Database for Short Genetic Variations (dbSNP) build 146, National Heart, Lung, and Blood Institute (NHLBI) Exome Variant Server, and Exome Aggregation Consortium (ExAC).

DISCUSSION {#s3}
==========

The patient presented with an unusually severe phenotype for autosomal dominant optic atrophy caused by an *OPA3* mutation. Certain aspects of her phenotype have been observed in others with heterozygous mutations in this gene, though rarely to this degree. In addition to the known features of optic atrophy and cataracts, she has peripheral motor and sensory neuropathy as well as evidence of autonomic neuropathy. Although neurological symptoms, such as extrapyramidal signs and ataxia, have been associated with autosomal dominant *OPA3* mutations, this is the first documented case of severe neuropathy ([@BOURNEMCS001156C6]; [@BOURNEMCS001156C10]). She also has occasional difficulties swallowing and frequent episodes of abdominal pain with alternating constipation and diarrhea. Gastrointestinal symptoms were also reported in a French family with a heterozygous c.313C \> G, p.(Gln105Glu) *OPA3* mutation ([@BOURNEMCS001156C2]).

The patient also has periodic lightheadedness, urinary symptoms, and a variable body temperature further suggesting autonomic nervous system involvement. Her urine organic acid profile (run twice on two different occasions) was normal with the exception of moderate ketone levels and the presence of myoglobin. Normal organic acid profiles are not uncommon in individuals with autosomal dominant *OPA3* mutations ([@BOURNEMCS001156C10]). She has pain in her extremities, reduced hearing in her left ear, and gait abnormalities, which are all previously associated with mutations in *OPA3* ([@BOURNEMCS001156C2]; [@BOURNEMCS001156C14]). She has also experienced rapid weight loss since age 20 and is now in the \<5th percentile of weight for her height. Metabolic testing was performed and the results showed that her resting energy expenditure was ∼84% of that predicted for her age, but an adjusted resting energy expenditure was calculated and was relatively high compared to controls similar to her size ([Supplemental Tables S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001156/-/DC1)--[S4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a001156/-/DC1)). Whether she has true lipodystrophy (abnormal growth and/or loss of adipose tissue due to a primary, intrinsic defect of the tissue) as opposed to lipoatrophy (loss of adipose tissue secondary to hypermetabolism) could not be established with certainty, though her relatively high metabolic rate suggests the possibility of the former. Mouse models with a homozygous mutation in *Opa3* showed a 60% reduction in body weight and profound intra-abdominal leanness, suggesting that the patient\'s loss of adipose tissue may be caused by her *OPA3* mutation ([@BOURNEMCS001156C5]; [@BOURNEMCS001156C18]; [@BOURNEMCS001156C8]). The atypical set of phenotypes observed in this case expands the phenotypic spectrum of autosomal dominant mutations in *OPA3* and identifies a de novo mutation, which we believe to be pathogenic for these phenotypes. However, additional functional studies or cases with a similar phenotype will be necessary to confirm the pathogenicity of autosomal dominant variants in *OPA3*.

METHODS {#s4}
=======

Exome Sequencing {#s4a}
----------------

Genomic DNA was extracted from whole blood collected from the affected patient and her parents and trio-based exome sequencing was performed at PerkinElmer corporation using Agilent V4 51Mb capture with sequencing of 100-bp paired-end reads on an Illumina HiSeq 2000 at average 30× coverage across the known exons ([Table 3](#BOURNEMCS001156TB3){ref-type="table"}). Data analysis was carried out using an in-house bioinformatics pipeline to align the FASTQ reads to the human genome reference version 19 (GRCh37.75) and to identify and assess the predicted effect of rare (\<3% allelic frequency from dbSNPv146) variants on protein function ([@BOURNEMCS001156C15]). De novo dominant-, recessive-, and X-linked modes of inheritance were assessed through in-house scripts, and variants altering the protein code were selected (missense, nonsense, frameshift changes, in-frame deletions, and splice-site effects) ([Table 4](#BOURNEMCS001156TB4){ref-type="table"}). Remaining variants were quality-screened manually using the Integrative Genomics Viewer (<https://www.broadinstitute.org/igv/>). The variants were narrowed down based on their clinical significance and similarity to the phenotype.

###### 

Sequence coverage

  Sample    Number of starting paired-end reads   Percentage of reads aligned   Median read coverage   Percentage of coding sites with \>20-fold coverage   Percentage of *OPA3* sites with \>10-fold coverage
  --------- ------------------------------------- ----------------------------- ---------------------- ---------------------------------------------------- ----------------------------------------------------
  Proband   67,382,674                            82.1                          37.5                   93.5                                                 100
  Mother    61,340,881                            79.3                          33.6                   90.1                                                 100
  Father    59,968,033                            83.6                          32.1                   88.6                                                 100

###### 

Variants identified from exome sequencing

                                            Filtering results   Manual review   Resulting genes of interest
  ----------------------------------------- ------------------- --------------- -----------------------------
  Homozygous (\# seq. changes)              4 (4)               0 (0)           0 (0)
  Compound heterozygous (\# seq. changes)   8 (16)              0 (0)           0 (0)
  De novo genes (\# seq. changes)           28 (28)             2 (2)           1 (1)
  X-linked genes (\# seq. changes)          9 (9)               1 (1)           0 (0)
  Total genes (\# seq. changes)             49 (57)             3 (3)           1 (1)

Sanger Sequencing {#s4b}
-----------------

Sanger sequencing of the variant of interest within the *OPA3* gene was carried out on DNA amplified by standard PCR. PCR reactions were prepared in a 20 µl volume with 40 ng genomic DNA, 1× GoTaq Green Mastermix (Promega), 5% dimethyl sulfoxide (DMSO) (Sigma-Aldrich), and 0.25 µM of the primer pair. Primers were designed by Life Technologies (*OPA3*, Hs00760967_CE; forward, 5′-GCCAGTACTCCAGCACTAGG-3′, reverse, 5′-CTGCATTCCCTGGGTGAGAG-3′). The PCR began with a 2-min cycle at 94°C, followed by 35 cycles of 45 sec at 94°C, 45 sec at 63°C, and 1 min at 72°C, ending with extension for 10 min at 72°C. Sanger sequencing was carried out on an ABI 3130xl.

Indirect Calorimetry {#s4c}
--------------------

The canopy (dilution) method was used to obtain indirect calorimetry information. Ambient and diluted fractions of O~2~ and CO~2~ were measured for a known ventilation rate. O~2~ consumption and CO~2~ production were determined and converted into resting energy expenditure. The abbreviated Weir equation (without urinary nitrogen) was used to convert gas exchange measures into resting energy expenditure.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

Exome sequencing data is not publicly available because patient consent could not be obtained. The variant found in the proband has been deposited into ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>) under accession number SCV000266846.
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